M&A

increase

Biotech

Biopharma biobucks decline, while upfront deal payments rise

While the average earnout potential per biopharma deal has declined over the last six years, the mean upfront value has been on the rise since 2017.

Gabrielle Masson Sep 24, 2025 11:30am

photo of a pair of binoculars perched on a rock aimed at the rising sun

Fierce Pharma

New Incyte CEO takes 'fresh look' at business, outlines BD plan

Aug 4, 2025 11:16am

Fierce Pharma

AbbVie will continue to pursue external innovation for long-term

Jul 31, 2025 11:44am

graphic of a larger shark chomping up a smaller one

US and UK CROs merge to form global company

Jul 15, 2025 5:52pm

team layoffs workforce

GSK plans 'very limited' job cuts for global R&D team

Jul 15, 2025 4:15pm

A chessboard with blocks that read MA

Sino Biopharm buys Merck’s PD-1xVEGF bispecific partner LaNova

Jul 15, 2025 10:16am